Pre-made Pasotuxizumab benchmark antibody ( Bispecific scFv, anti-FOLH1/GCPII;CD3E therapeutic antibody, Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-429

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-429 Category Tags ,

Product Details

Pre-Made Pasotuxizumab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Pasotuxizumab is a PSMA x CD3 BiTE immune therapy that mediates killing of tumor cells by T cells.

Products Name (INN Index)

Pre-Made Pasotuxizumab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody

INN Name

Pasotuxizumab

Target

FOLH1,CD3E

Format

Bispecific scFv

Derivation

Bispecific antibody

Species Reactivity

Human

CH1 Isotype

NA

VD LC

Kappa,Lambda

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Discontinued

100% SI Structure

None;None

99% SI Structure

None;None

95-98% SI Structure

None;None

Year Proposed

2014

Companies

Amgen,Bayer HealthCare Pharmaceuticals,Micromet Inc

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Prostate cancer

Development Tech

BiTE Technology

Previous Name

NA

Gm Offical Target Name

FOLH1,CD3E

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide